Pfizer's headquarters in New York. Photo: Bess Adler/Bloomberg via Getty Images
Pfizer on Monday said it has agreed to buy cancer drugmaker Seagen for $43 billion in cash.
Why it matters: This is the largest merger announcement so far in 2023, and the largest pharma deal since Abbvie bought Allergan in 2020.
- It also reflects how Pfizer is using its COVID vaccine fortune to bolster its other businesses.
Details: Pfizer will pay $229 per share in cash, representing a 32.7% premium to where Seagen shares closed trading last Friday.
More, from FiercePharma: "Pfizer's largest oncology asset, breast cancer drug Ibrance, has been on decline. Collaboration revenue around Astellas-shared prostate cancer med Xtandi has been flat. And Pfizer's commercial and pipeline portfolios lack new star products that could move the market … Seagen is an attractive target with four commercial medicines and many more likely coming in its deep pipeline full of antibody-drug conjugate candidates."
Source: Read Full Article
Jonathan Grace, of Colorado, charged in U.S. Capitol riot on Jan. 6
Fidelity again marks down its Twitter shares
The Block lays off a third of staffers amid leadership shakeup
Putin calling up 147,000 men from tomorrow as battlefield slaughter intensifies
Wagner convict granted pardon for serving in Ukraine accused of murder